Blood-brain barrier integrity decreases with higher blood 1

pressure, a 7T DCE-MRI study 2

3

26

4	Marieke van den Kerkhof ^{1,2} , Joost J.A. de Jong ^{1,2} , Paulien H.M. Voorter ^{1,2} , Alida Postma ^{1,2} ,
5	Abraham A. Kroon ^{3,4} , Robert J. van Oostenbrugge ^{2,4,5} , Jacobus F.A. Jansen ^{1,2,6} , Walter H. Backes ^{1,2,4}
6	
7	¹ Department of Radiology & Nuclear Medicine, Maastricht University Medical Center, Maastricht,
8	The Netherlands;
9	² School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands;
10	³ Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The
11	Netherlands;
12	⁴ School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands;
13	⁵ Department of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands;
14	⁶ Department of Electrical Engineering, Eindhoven University of Technology, Eindhoven, the
15	Netherlands
16	
17	Corresponding author: W.H. Backes, Department of Radiology & Nuclear Medicine, Maastricht
18	University Medical Center, PO Box 5800, 6202 AZ, Maastricht, the Netherlands. E-mail:
19	w.backes@mumc.nl
20	
21	Word count: 5882
22	
23	Short title: Blood-brain barrier leakage and high blood pressure
24	
25	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 Abstract

28 Background

Blood-brain barrier (BBB) integrity is presumed to be impaired in hypertension, resulting
from cerebral endothelial dysfunction. Hypertension antedates various cerebrovascular
diseases, such as cerebral small vessel disease (cSVD), and is a risk factor for developing
neurodegenerative diseases for which BBB disruption is a preceding pathophysiological
process. In this study, we investigated the relation between hypertension, current blood
pressure and BBB leakage in human subjects.

35 Methods

36 BBB leakage was determined in twenty-two patients with hypertension and nineteen

normotensive controls, age- and sex-matched (median age[range]:65[45-80] years,19 males),

38 using a sparsely time-sampled contrast-enhanced 7 Tesla MRI protocol. Structural cSVD

39 markers were visually rated. Multivariable regression analyses, adjusted for age, sex,

40 cardiovascular risk factors and cSVD markers, were performed to determine the relation

41 between hypertension status, systolic and diastolic blood pressure (SBP and DBP), mean

42 arterial pressure (MAP), drug treatment, and BBB leakage.

43 **Results**

44 Both hypertensive and normotensive participants showed mild scores of cSVD. BBB leakage

45 did not differ between hypertensive and normotensive participants, however was significantly

46 higher for SBP, DBP and MAP in the cortex, and DBP and MAP in the grey matter.

47 Effectively treated patients showed less BBB leakage than those with current hypertension.

48 Conclusion

49 BBB integrity in the total and cortical grey matter decreases with increasing blood pressure,

50 but is not related to hypertension status. These findings show that BBB disruption already

51 occurs with increasing blood pressure, before the presence of overt cerebral tissue damage.

52	Additionally, our results suggest that effective antihypertensive medication has a protective
53	effect on the BBB.
54	
55	Registered at: https://trialsearch.who.int/; Unique identifier: NL7537
56	Keywords: blood-brain barrier leakage, DCE-MRI, 7 Tesla, hypertension, high blood pressure
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	

79 Non-standard Abbreviations and Acronyms

- 80 BBB blood-brain barrier
- 81 cSVD cerebral small vessel disease
- 82 DBP diastolic blood pressure
- 83 DCE-MRI dynamic contrast enhanced magnetic resonance imaging
- 84 GM grey matter
- 85 MAP mean arterial pressure
- 86 PVS perivascular spaces
- 87 ROI region of interest
- 88 SBP systolic blood pressure
- TE echo time
- 90 TR repetition time
- 91 VIF vascular input function
- $92 \quad WM white matter$
- 93 WMH white matter hyperintensities

94

- 96
- 97
- 98
- 99
- . . .
- 100
- 101
- 102
- 103
- 104

105 Introduction

Hypertension is a highly prevalent condition, and its incidence increases in an aging 106 107 population.¹ In addition to the heart and kidneys, the brain is highly susceptible to high blood 108 pressure, which consequently may result in neurological diseases, such as stroke and 109 dementia.² Hypertension causes vascular remodelling, which includes both structural and 110 functional alterations of the vessel walls. Over time, these changes lead to endothelial 111 dysfunction and to breakdown of the blood-brain barrier (BBB), with a detrimental effect on the neuronal microenvironment and brain health.^{3,4} 112 113 The BBB is a highly specialized structure in the cerebral vessel walls and preserves the 114 biological homeostasis of the central nervous system through selective supply of nutrients to the brain tissue and removal of waste products.⁵ Loss of BBB integrity increases the 115 116 permeability of this barrier, and thereby allows neurotoxins to accumulate in the brain tissue. 117 Although hypertension is assumed to have a negative effect on BBB integrity, the precise 118 pathophysiology has not yet been elucidated. Potentially, vascular oxidative stress and 119 inflammation lead to dysfunction of endothelial cells and degeneration of pericytes, consequently resulting in a disrupted BBB.³ A large number of studies have investigated BBB 120 121 impairment and hypertension in animal studies and found an increased permeability in several 122 regions for hypertensive models.⁶ Others reported subtle BBB impairment in human patients with disorders such as preeclampsia, cerebral small vessel disease (cSVD), and dementia.⁷⁻¹⁰ 123 124 While it is often assumed that hypertension leads to BBB disruption, the relation of 125 hypertension or high blood pressure and BBB permeability has not yet been investigated 126 explicitly in human subjects. 127 The most commonly used technique to measure BBB integrity is dynamic contrast-enhanced

128 (DCE) MRI. This method uses the intravenous administration of a paramagnetic contrast

agent, which is subsequently followed over time by acquiring a continuous series of MRI

130	scans after contrast administration. The leakage of the contrast agent from the blood
131	circulation to the brain tissue is quantified by the signal intensity changes, and converting
132	these temporal changes to blood concentrations. Recently, we proposed a highly sensitive
133	DCE-method at 7 Tesla, where instead of the commonly continuously acquired T_1 -weighted
134	images, only two quantitative post-contrast T ₁ -maps were acquired. ¹¹
135	In the current study, we investigated the relation between hypertension, blood pressure and
136	BBB leakage in human subjects. Therefore, we applied the sparsely time-sampled, dynamic
137	contrast-enhanced MRI protocol to patients with essential hypertension and normotensive,
138	healthy controls, to investigate group differences in BBB leakage rates.
139	

140 *Methods*

141 *Data availability*

142 The data that support the findings of this study are available from the corresponding author143 upon reasonable request.

144

145 *Study population*

146 Between July 2019 and July 2021, 23 patients with essential hypertension and 20 147 normotensive, healthy controls were included, matched on age and sex. The patients with 148 essential hypertension were recruited from the outpatient internal medicine clinic of the 149 Maastricht University Medical Center, The Netherlands, and through a recruitment website 150 (hersenonderzoek.nl). Essential hypertension was defined as a mean blood pressure of ≥ 135 151 mmHg systolic or \geq 85 mmHg diastolic, or both, when measured for 30 minutes with an 152 automated blood pressure monitor. Additionally, participants who took antihypertensive 153 medication were also defined as hypertensive. The recruitment of healthy controls took place 154 via advertisements in the local newspaper, in the hospital, and on a recruitment website

155	(hersenonderzoek.nl). Inclusion criteria for all participants were: age between 30-90 years old
156	and eligibility to undergo 7 Tesla MRI with contrast agent administration. Exclusion criteria
157	were history of secondary hypertension, diabetes mellitus, ischemic heart disease,
158	hemorrhagic stroke, or preeclampsia, and no diagnosis of obstructive sleep apnea syndrome,
159	body mass index (BMI) > 32 kg/m^2 , and contraindications for the gadolinium-containing
160	contrast agent, including glomerular filtration rate (eGFR) <30 mL/min.
161	Before study participation, all participants gave written informed consent. The study was
162	approved by the local Medical Ethical Committee of Maastricht University Medical Center
163	(Trial NL7537).
164	
165	Demographics
166	Demographics were recorded, which included age, sex, type of antihypertensive medication
167	(if applicable), other types of medication (if applicable), BMI, smoking status (current and
168	history) and alcohol use.
169	
170	Blood pressure measurement
171	All participants underwent automated blood pressure measurement (Dinamap, GE Healthcare

172 Chicago, USA) preceding the MRI-scan, which was performed on the same day. This

173 measurement was performed by the same trained investigator for all participants (MvdK).

174 First, the blood pressure was consecutively determined at both arms with a single

175 measurement. The arm which acquired the highest blood pressure was used for the subsequent

176 measurements every 5 minutes during 30-45 minutes. Throughout this time, the participant

- 177 was kept seated solitary in the room, and was instructed to stay awake. To obtain the blood
- 178 pressure characteristics, the last five measurements were averaged and used in the data

analysis, yielding systolic and diastolic blood pressure (SBP and DBP, respectively), andmean arterial pressure (MAP).

- 181
- 182 *MRI*

183 Brain images were acquired with a 7 Tesla MRI (Magnetom, Siemens Healthineers, Erlangen, 184 Germany) using a 32-channel phased-array head coil. Dielectric pads were placed on both 185 sides of the participant's neck, proximal to the temporal lobes, for improvement of B1+ field 186 homogeneity across the brain. Anatomical and DCE-images were acquired. The DCE-187 protocol consisted of quantitative precontrast 3D T1 mapping using a Magnetization-Prepared 188 2 Rapid Acquisition Gradient Echo (MP2RAGE) sequence (TR/TE = 5000/2.47 ms, TI₁/TI₂ = 189 2700/900 ms, cubic voxel size = 0.7 mm, acquisition time = 8:00 min:s), followed by a 3D 190 fast gradient echo T1-weighted perfusion (volumetric interpolated brain examination, VIBE) 191 sequence (TR/TE = 3.7/1.3 ms, cubic voxel size = 2.0 mm, acquisition time = 2:47 min:s). 192 After the first three volumes were acquired, the contrast agent (1.0 molar Gadobutrol, 3 mL 193 for each participant) was injected with an infusion rate of 0.3 mL/s followed by a saline flush 194 (20 mL). Finally, two postcontrast T1 maps (TR/TE = 4000/2.32 ms, TI₁/TI₂ = 2700/900 ms, 195 cubic voxel size = 1.2 mm, acquisition time = 4:16 min:s) were acquired, of which the first 196 postcontrast T1 map was acquired immediately after the dynamic perfusion scan series and 197 the last T1 map was acquired approximately 25 minutes after the start of CA injection. More 198 details about the scan parameters and this protocol are reported in Table S1 and Kerkhof et al. 199 (2021).¹¹ For optimal segmentation of grev matter (GM) and white matter (WM), a T2-200 weighted fluid-attenuated inversion recovery (FLAIR) sequence (TR/TE/TI = 8000/303/2330 201 ms; cubic voxel size: 1 mm, acquisition time: 6:59 min:s) was acquired in between the two 202 postcontrast T1-maps. Additionally, for the rating of microbleeds and perivascular spaces 203 (PVS), a susceptibility weighted imaging (SWI) sequence was acquired before contrast

administration, and T2-weighted images were acquired after contrast administration,

205 respectively.

206

207 Image analysis

208 Preprocessing of the quantitative T1 maps consisted of bias field correction, skull stripping 209 and gradient distortion correction. To correct for head displacements, all acquired images 210 were spatially registered to the same reference image, which was the first postcontrast T1 211 map. Subsequently, GM and WM were automatically segmented using the precontrast T1 and FLAIR images as input (FreeSurfer version 6.0.5).¹² The segmentations were visually 212 213 verified, and manually corrected when required. This resulted in four tissue regions of interest 214 (ROI): total GM and total WM, cortical and deep GM). The subject-specific vascular input 215 function (VIF) was derived from an ROI manually delineated in the superior sagittal sinus. 216 217 The leakage maps were determined by applying the graphical Patlak approach to the 218 concentration time-courses of each brain tissue voxel and the VIF, resulting in a Patlak plot, 219 in which the slope represents the BBB leakage rate, K_i [min⁻¹], and the intercept yields the blood plasma volume fraction, v_p [-].¹³ Per ROI, the mean K_i and v_p of all voxels within each 220 221 ROI were calculated and used as physiological measures. Outlier correction was performed by considering the K_i and v_p values in these ROIs located in the 95% confidence interval.¹¹ 222 223 All data analyses were performed using custom-made code in the Matlab programming 224 environment (2019b, 9.2.0; Mathworks, Nattick, MA, USA). 225 226 *cSVD* rating

227 Four cSVD-markers, i.e., white matter hyperintensities (WMH), lacunar infarcts, microbleeds

and MRI-visible PVS, were visually rated by one trained neuroscientist (MvdK: >2 years of

229 experience) under supervision of an experienced neuroradiologist (AAP: >20 years of experience) and were combined into a global cSVD-score per participant.¹⁴ The WMH load 230 was rated using the Fazekas scale.¹⁵ When (early) confluent deep white matter 231 hyperintensities were present (Fazekas score 2 and 3) or irregular periventricular 232 hyperintensities which extended into the deep white matter (Fazekas score 3), one point was 233 assigned to the global cSVD-score.¹⁴ Furthermore, one point was assigned when 1 or more 234 asymptomatic lesions, i.e., lacunar infarcts, were present.¹⁶ Another point was assigned when 235 236 1 or more microbleeds were present in the basal ganglia, since these were associated with hypertension.¹⁶ Lastly, PVS were rated in the basal ganglia, as these have also been shown to 237 be associated with hypertension.^{17,18} The PVS score was established in the slice with the 238 239 highest number of PVS, and graded in four groups: $0 \le 10$, 1: 11-25, 2: 26-40, $3 \ge 41$ PVS, as previously published.¹⁹ A last point was assigned to the cSVD-score if moderate to 240 241 extensive PVS (score 1-3) were present. These points combined could yield a maximum 242 cSVD-score of 4 points.

243

244 *Statistics*

To examine the differences in characteristics between hypertensive patients and controls,
Pearson chi-square or Fisher's exact tests were applied for categorical variables when
appropriate. For continuous variables independent Student's *t*-tests were performed. Outliers
were defined as a data point with a deleted studentized residual higher than 3.5, and Cook's
distance higher than 1.

First, we set out to determine the association between K_i or v_p in the ROIs (i.e., total GM, total WM, deep GM, cortical GM) with hypertension status by performing multivariable linear regression analyses, corrected for age and sex. Additionally, multivariable linear regression analyses corrected for age and sex were applied to investigate the relation between the

254 measured blood pressure characteristics – SBP, DBP and MAP – and the K_i and v_p in the brain 255 ROIs. Furthermore, these analyses were repeated while alternately adjusting for relevant 256 cardiovascular risk factors, which are BMI, alcohol use, history of smoking, and hematocrit 257 level. Intake of antihypertensive medication and cholesterol lowering medication was also 258 considered alternately in the regression analyses. Lastly, to study the potential influence of 259 cSVD on the associations, the analyses were adjusted by total cSVD score. 260 An additional post-hoc analysis was performed to explore the difference in leakage measures 261 between the subgroups of hypertensive patients, which were based on the measured blood pressure on the day of the MRI-scan, and their blood pressure medication intake. This resulted 262 263 in three subgroups: NT+: patients who had normal blood pressure levels, using 264 antihypertensive medication (n=12), HT-: patients with high blood pressure, without using antihypertensive medication (n=5), and HT+: patients with high blood pressure, despite of 265 266 using antihypertensive medication (n=5). To explore the between-group differences, ANOVA 267 with post-hoc Tukey tests were performed. A *P*-value < 0.05 was considered statistically significant. All statistical analyses were 268

269 conducted using SPSS (version 28.0, Chicago, IL).

270

271 Results

The group characteristics of the hypertensive patients (n = 22 with a mean age of 66 years of whom 64% are female) and the controls (n = 19 with a mean age of 62 years, of whom 42% are female) who were included for the final analysis are listed in Table 1. One control participant and one hypertensive patient were identified as outliers in terms of leakage rates and therefore excluded from further analysis. SBP was found to be significantly higher for the hypertensive patients than for the controls. No significant differences in blood pressure measures, age, sex, cardiovascular risk factors, blood measures, or cSVD scores were found.

279	Examining the association between sex and K_i showed that the leakage rate was significantly
280	higher in males ($P < 0.001$ in all regions), but no significant relation with age was found.
281	

282 The K_i in hypertensive patients did not significantly differ from the K_i in healthy controls,

while adjusting for age and sex (Table 2). In contrast, v_p was significantly higher for

hypertensive patients in all GM ROIs and showed a comparable trend for the entire WM.

Positive significant relations of K_i with systolic and DBP and MAP were obtained in the

cortical GM and for DBP and MAP in total GM (Table 3). *K_i* versus SBP yielded a positive

trend towards significance in total GM. No significant relations were found for SBP, DBP and

288 MAP with K_i in WM and deep GM. For v_{p_i} no significant relations were found with blood

289 pressure measures.

290 The scatterplots in Figure 1 show the relation between K_i and MAP in the four ROIs in more

detail. Supplemental Figure 1 illustrates the relation between v_p and MAP in the four ROIs.

292

293 Cardiovascular risk factors

294 The obtained relations between K_i and DBP, and K_i and MAP remained significant after alternately adjusting for cardiovascular risk factors, medication intake and cSVD score. When 295 296 considering BMI, alcohol intake, and cSVD score in the regression analyses with SBP in the 297 cortical GM, the adjusted relations did not remain significant, but still showed a positive trend 298 towards significance ($\beta = 0.216$, P = 0.062, $\beta = 0.245$, P = 0.053 and $\beta = 0.245$, P = 0.059, respectively). For total GM, the relation was found to be significant when correcting for 299 300 history of smoking or intake of cholesterol medication ($\beta = 0.231$, P = 0.050 and $\beta = 0.233$, P301 = 0.049, respectively).

302

304 *Subgroup analyses*

305	Post-hoc analysis of the hypertensive subgroups (HT+, HT-, and NT+) revealed a trend
306	towards significance of higher K_i in HT+ compared to NT+ patients for the grey matter
307	regions (cortex: $P = 0.098$, total GM: $P = 0.088$, deep GM: $P = 0.058$), but not for WM. After
308	pooling of the HT- and HT+ patients, the NT+ group demonstrated lower leakage rates than
309	the combined HT group for the total and cortical GM ($P = 0.021$ and $P = 0.016$, respectively).
310	Figure 3 shows the corresponding boxplot for the cortex as an example. Boxplots for K_i in the
311	total GM, deep GM and total WM can be found in Supplemental Figure 2. Post-hoc analysis
312	for v_p did not show significant differences between subgroups.

313

314 Discussion

315 In this study, we set out to investigate the relationship between hypertension, SBP, DBP and 316 MAP, and BBB leakage measured with a highly sensitive DCE-protocol at 7 Tesla MRI in 317 human subjects. Based on dichotomous hypertension status, we found no relation with BBB 318 leakage. For the individual blood pressure characteristics, i.e., SBP, DBP and MAP, a higher 319 blood pressure was associated with stronger BBB leakage in the grey matter and not in the 320 white matter. The results were independent of cardiovascular risk factors and presence of 321 cSVD imaging markers. Medically well treated patients (NT+) showed less BBB leakage than 322 patients with current hypertension (pooled HT- and HT+ group).

323

The BBB is often assumed to become impaired due to the pathophysiological pathway as a consequence of hypertension.^{2,6} To investigate whether increased blood pressure impacts the BBB integrity prior to the presence of overt cerebral tissue damage, this research focused on differences in BBB leakage between hypertensive patients with no known cerebrovascular disease and normotensive controls. The lack of differences in BBB leakage found between the

329 hypertensive and normotensive group, is likely due to the similarities of the blood pressure 330 characteristics of the two groups. SBP was the only blood pressure measure found to be 331 higher in the hypertensive patients. In addition to the groups being matched beforehand on 332 age and sex, the other cardiovascular risk factors, blood measures, and cSVD scores were also found to be similar across the two groups. However, we observed a large variation in BBB 333 334 leakage in the hypertensive patients (NT+, HT-, and HT+), which also could explain the 335 absence of a difference in BBB leakage between the hypertension versus normotension group. 336 This demonstrates a large influence of current blood pressure (as opposed to hypertension 337 status) on the BBB integrity. The observed relation between current blood pressure and BBB 338 leakage suggests that a higher blood pressure could lead to endothelial dysfunction, impairing 339 the permeability of the barrier.

340

In the GM, a positive relation between blood pressure and BBB leakage was obtained. In contrast, no relation was obtained within the WM. Our findings imply that in grey matter, especially in the well perfused cortical grey matter, subtle leakage is easier, and therefore earlier, to detect than in the less perfused white matter. Additionally, the tissue around the basal ganglia, thus WM, is more protected from the effects of cerebrovascular dysfunction as these arterioles contain two layers, whereas the superficial perforating arterioles have only one layer.²⁰

348

Previous studies using hypertension models in animals showed that a higher BBB
permeability is related to hypertension^{6,21,22}, although some studies did not find any
differences in hypertensive animal models.^{23,24} It should be noted that these studies use
different methods of measuring BBB leakage, as they use other contrast agents, such as
fluorescently labeled dextran or lectin.^{21,22,25} Furthermore, these studies are able to dissect the

brain after imaging, to investigate the neurovascular properties in more detail. Studies on
BBB leakage in humans often focus on diagnosed cerebrovascular diseases, such as cSVD
and (mixed) dementia.^{8,9,26,27} These studies demonstrated stronger BBB leakage in these
patients, and showed that hypertension is a significant covariate. However, they did not
investigate hypertension as a separate condition, or in subjects without overt neurovascular
disease.

360 The associations with blood plasma volume fraction were contrary to the findings of the

361 leakage rate in this study. Differences in blood plasma volume fraction were found in

362 hypertensive patients versus normotensive controls, based on dichotomous status, while no

363 relations were found for the current blood pressure measures. These results are contradictory

to the pathway of a reduced cerebral blood flow, which is related to the blood plasma volume

365 fraction, in hypertension. However, the higher blood plasma volume in hypertensive patients

is not indicative of an advanced cerebrovascular disease stage, as vessels tend to narrow

367 (lower blood volume or flow) in a more advanced hypertensive disease state.²⁸

368

369 As previous studies showed an association between age and sex, and BBB leakage, we

initially adjusted for these two covariates.^{31–33} We indeed found a strong correlation between

371 sex and leakage measures, indicating that women have a lower BBB permeability compared

to men. This effect could be explained by the hormonal differences between men and women,

373 as female hormones, such as estrogen, may act neuroprotective. 32,33

374

375 Cardiovascular risk factors

376 This study assessed several cardiovascular risk factors, as well as a cSVD score which was

377 rated on a scale based on previous literature and reflects the total cSVD burden.^{14,29} All

378 observed associations remained significant after adjusting for these covariates. In contrast to

our findings, previous studies showed that cSVD was associated with higher BBB leakage.^{8,30}
The low number of cSVD markers observed in our population compared to the more severe
cSVD rates in other studies could account for this divergence. We therefore emphasize that in
this study, we set out to measure this specific consequence of microvascular damage in a
rather early stage of (or mild) cSVD.

384

385 *Hypertension subgroups*

386 As mentioned above, our results show a large effect on the BBB leakage rate of the actual 387 blood pressure, measured preceding the MRI examination, rather than hypertension status. 388 While comparing the leakage rates between the hypertensive subgroups, a trend of stronger 389 BBB leakage was found in hypertensive patients with inadequate antihypertensive medication 390 (HT+), compared to patients with effective antihypertensive medication (NT+). The HT-391 group tends to be associated with higher BBB leakage values than the NT+ group, but only 392 slightly lower values than the HT+ group. As the HT+ group does not show significantly 393 higher or lower values than the HT- group, and the combined HT group obtained higher 394 leakage values than the NT+ group, we suggest that effective medication has a protective 395 effect on BBB permeability. Previous studies also have shown such restoring effects of specific antihypertensive medication in hypertensive rat models.⁶ However, it is important to 396 397 be aware of the small sample size of the subgroups.

398

399 Strengths and limitations

This study focused on BBB leakage in patients with high blood pressure, without known
cerebrovascular diseases, compared to normotensive controls. The strength of this study
design is that it enabled the investigation of early BBB changes, before neurovascular damage
is visible on the MRI scans and before subjects experience neurological complaints.

Furthermore, a sparsely sampled, interleaved MRI protocol was used to obtain subtle BBB 404 405 measures, which shortened the scanning time substantially compared to frequently used DCE 406 sequences lasting up to 30 minutes. This protocol also allows for other imaging sequences to 407 be scanned in between, allowing to use the scanning time more efficient. Furthermore, using 408 high-field 7T MRI enhances the signal-to-noise ratio with increasing spatial resolution, 409 thereby enabling improved measurement of subtle BBB leakage. 410 There are several methodological considerations. The blood pressure was measured using a 411 30-minute during automatic protocol, although the most accurate method would be 24-hour 412 ambulatory blood pressure monitoring. Regardless, the blood pressure measurement protocol in this study is validated to be the second most accurate method.³⁴ 413 414 As discussed, the cSVD scores were relatively low in our population. Future studies should 415 also include participants with higher cSVD scores to improve the ability of investigating BBB 416 leakage in patients with hypertension with varying amounts of visibly developed 417 neurovascular disease. 418 Larger sample sizes in the three hypertension subgroups, or a longitudinal study design 419 (before and after start of antihypertensive treatment) would also be recommended in future 420 research that focuses on studying medication effects on BBB leakage in more detail. While 421 previous studies show varying effects between the different types of antihypertensive 422 medication, our study did not have enough power in the subgroups to draw definite 423 conclusions, as our study was not designed for this specific aim. 424 425 **Perspectives** 426 To summarize, this study aimed to investigate the relationship between BBB integrity, high

427 blood pressure and hypertension. For the dichotomous hypertension status, no significant

428 effects of BBB leakage were found. However, when looking at continuous blood pressure

429	measures, a strong positive relation was found between leakage in the cortical grey matter and
430	current blood pressure. A protective function of antihypertensive medication was observed,
431	but future studies should include more hypertensive patients or engage a longitudinal study
432	design to investigate this in more detail.
433	
434	Acknowledgements
435	We thank the technicians of Scannexus for assisting with scanning and the administration of
436	the contrast agent.
437	
438	Sources of Funding
439	This study was partly funded by the EU's Horizon 2020 project 'CRUCIAL', Grant
440	agreement number 848109, and 'Stichting De Weijerhorst Foundation'.
441	
442	Disclosures
443	None
444	
445	Supplemental Material
446	Figure S1-S2
447	Tables S1
448	
449	
450	
451	
452	

454 **References**

- Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. *Nat. Rev. Nephrol.* 2020;16:223–237.
- 457 2. Faraco G, Iadecola C. Hypertension: A Harbinger of Stroke and Dementia.
- 458 *Hypertension*. 2013;62:810–817.
- 459 3. Iadecola C, Yaffe K, Biller J, Bratzke LC, Faraci FM, Gorelick PB, Gulati M, Kamel H,
- 460 Knopman DS, Launer LJ, et al. Impact of Hypertension on Cognitive Function: A
- 461 Scientific Statement From the American Heart Association. *Hypertension*. 2016;68.
- 462 4. Meissner A. Hypertension and the Brain: A Risk Factor for More Than Heart Disease.
 463 *Cerebrovasc. Dis.* 2016;42:255–262.
- 464 5. Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-Brain Barrier:
 465 From Physiology to Disease and Back. *Physiol. Rev.* 2019;99:21–78.
- 466 6. Katsi V, Marketou M, Maragkoudakis S, Didagelos M, Charalambous G, Parthenakis F,
- 467 Tsioufis C, Tousoulis D. Blood–brain barrier dysfunction: the undervalued frontier of
 468 hypertension. *J. Hum. Hypertens.* 2020;34:682–691.
- 469 7. Canjels LPW, Jansen JFA, Alers RJ, Ghossein-Doha C, Van Den Kerkhof M, Schiffer
- 470 VMMM, Mulder E, Gerretsen SC, Aldenkamp AP, Hurks PPM, et al. Blood–brain
- 471 barrier leakage years after pre-eclampsia: dynamic contrast-enhanced 7-TESLA MRI
- 472 study. Ultrasound Obstet. Gynecol. 2022;60:541–548.
- 8. Thrippleton MJ, Backes WH, Sourbron S, Ingrisch M, van Osch MJP, Dichgans M,
 Fazekas F, Ropele S, Frayne R, van Oostenbrugge RJ, et al. Quantifying blood-brain

475 barrier leakage in small vessel disease: Review and consensus recommendation
--

476 *Alzheimers Dement.* 2019;15:840–858.

477	9.	Dobrynina LA,	Shamtieva KV,	Kremneva EI,	Zabitova MR	, Akhmetzyanov Bl	М,
-----	----	---------------	---------------	--------------	-------------	-------------------	----

- 478 Gnedovskaya EV, Krotenkova MV. Daily blood pressure profile and blood–brain barrier
- permeability in patients with cerebral small vessel disease. *Sci. Rep.* 2022;12:7723.
- 480 10. Raja R, Rosenberg GA, Caprihan A. MRI measurements of Blood-Brain Barrier

481 function in dementia: A review of recent studies. *Neuropharmacology*. 2018;134:259–

482 271.

483 11. Kerkhof M, Voorter PHM, Canjels LPW, Jong JJA, Oostenbrugge RJ, Kroon AA,

484 Jansen JFA, Backes WH. Time-efficient measurement of subtle blood-brain barrier

485 leakage using a T₁ mapping MRI protocol at 7 T. *Magn. Reson. Med.* 2021;85:2761–
486 2770.

487 12. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A,
488 Killiany R, Kennedy D, Klaveness S, et al. Whole Brain Segmentation. *Neuron*.
489 2002;33:341–355.

490 13. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical Evaluation of Blood-to-Brain
491 Transfer Constants from Multiple-Time Uptake Data. *J. Cereb. Blood Flow Metab.*492 1983;3:1–7.

493 14. Staals J, Makin SDJ, Doubal FN, Dennis MS, Wardlaw JM. Stroke subtype, vascular
494 risk factors, and total MRI brain small-vessel disease burden. *Neurology*. 2014;83:1228–
495 1234.

- 496 15. Fazekas F, Chawluk J, Alavi A, Hurtig H, Zimmerman R. MR signal abnormalities at
- 497 1.5 T in Alzheimer's dementia and normal aging. *Am. J. Roentgenol.* 1987;149:351–356.
- 498 16. Klarenbeek P, van Oostenbrugge RJ, Rouhl RPW, Knottnerus ILH, Staals J. Ambulatory
- Blood Pressure in Patients With Lacunar Stroke: Association With Total MRI Burden of
- 500 Cerebral Small Vessel Disease. *Stroke*. 2013;44:2995–2999.
- 501 17. Wardlaw JM, Benveniste H, Nedergaard M, Zlokovic BV, Mestre H, Lee H, Doubal FN,
- 502 Brown R, Ramirez J, MacIntosh BJ, et al. Perivascular spaces in the brain: anatomy,
- 503 physiology and pathology. *Nat. Rev. Neurol.* 2020;16:137–153.
- Francis F, Ballerini L, Wardlaw JM. Perivascular spaces and their associations with risk
 factors, clinical disorders and neuroimaging features: A systematic review and metaanalysis. *Int. J. Stroke*. 2019;14:359–371.
- 507 19. Kerkhof M van den, Thiel MM van der, Oostenbrugge RJ van, Postma AA, Kroon AA,
- 508 Backes WH, Jansen JF. Impaired damping of cerebral blood flow velocity pulsatility is
- 509 associated with the number of perivascular spaces as measured with 7T MRI. J. Cereb.
- 510 Blood Flow Metab. 0:0271678X231153374.
- 511 20. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel
 512 disease: insights from neuroimaging. *Lancet Neurol.* 2013;12:483–497.
- 513 21. Santisteban MM, Iadecola C, Carnevale D. Hypertension, Neurovascular Dysfunction,
 514 and Cognitive Impairment. *Hypertension*. 2023;80:22–34.
- 515 22. Biancardi VC, Son SJ, Ahmadi S, Filosa JA, Stern JE. Circulating Angiotensin II Gains
- 516 Access to the Hypothalamus and Brain Stem During Hypertension via Breakdown of the
- 517 Blood–Brain Barrier. *Hypertension*. 2014;63:572–579.

518	23.	Naessens DMP, De Vos J, VanBavel E, Bakker ENTP. Blood-brain and blood-
519		cerebrospinal fluid barrier permeability in spontaneously hypertensive rats. Fluids
520		Barriers CNS. 2018;15:26.
521	24.	Rodrigues SF, Granger DN. Cerebral Microvascular Inflammation in DOCA Salt-
522		Induced Hypertension: Role of Angiotensin II and Mitochondrial Superoxide. J. Cereb.
523		Blood Flow Metab. 2012;32:368–375.
524	25.	Santisteban MM, Ahn SJ, Lane D, Faraco G, Garcia-Bonilla L, Racchumi G, Poon C,
525		Schaeffer S, Segarra SG, Körbelin J, et al. Endothelium-Macrophage Crosstalk Mediates
526		Blood-Brain Barrier Dysfunction in Hypertension. Hypertension. 2020;76:795-807.
527	26.	Chagnot A, Barnes SR, Montagne A. Magnetic Resonance Imaging of Blood-Brain
528		Barrier permeability in Dementia. <i>Neuroscience</i> . 2021;474:14–29.
529	27.	Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer
530		disease and other neurodegenerative disorders. Nat. Rev. Neurol. 2018;14:133-150.
531	28.	Iadecola C, Gottesman RF. Neurovascular and Cognitive Dysfunction in Hypertension:
532		Epidemiology, Pathobiology, and Treatment. Circ. Res. 2019;124:1025-1044.
533	29.	Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI,
534		O'Brien JT, Barkhof F, Benavente OR, et al. Neuroimaging standards for research into
535		small vessel disease and its contribution to ageing and neurodegeneration. Lancet
536		Neurol. 2013;12:822–838.
537	30.	Wong SM, Jansen JFA, Zhang CE, Staals J, Hofman PAM, van Oostenbrugge RJ,
538		Jeukens CRLPN, Backes WH. Measuring subtle leakage of the blood-brain barrier in
539		cerebrovascular disease with DCE-MRI: Test-retest reproducibility and its influencing

540	factors: Reproducibility of DCE-MRI in Subtle	e Leakage. J. Magn	. Reson. Imaging.
-----	---	--------------------	-------------------

- 541 2017;46:159–166.
- 542 31. Verheggen ICM, De Jong JJA, Van Boxtel MPJ, Gronenschild EHBM, Palm WM,
- 543 Postma AA, Jansen JFA, Verhey FRJ, Backes WH. Increase in blood-brain barrier
- leakage in healthy, older adults. *GeroScience*. 2020;42:1183–1193.
- 545 32. Weber CM, Clyne AM. Sex differences in the blood–brain barrier and
- neurodegenerative diseases. *APL Bioeng.* 2021;5:011509.
- 547 33. Dion-Albert L, Bandeira Binder L, Daigle B, Hong-Minh A, Lebel M, Menard C. Sex
- 548 differences in the blood–brain barrier: Implications for mental health. *Front*.
- 549 *Neuroendocrinol.* 2022;65:100989.
- 550 34. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL,
- 551 Coca A, De Simone G, Dominiczak A, et al. 2018 ESC/ESH Guidelines for the
- management of arterial hypertension. *Eur. Heart J.* 2018;39:3021–3104.
- 553
- 554
- 555
- 556
- 557
- 558
- 559
- 560
- 561
- 562
- 563

564 Figure legends

565	Figure 1: Scatterplots of the blood-brain barrier leakage rate in the four regions of interest
566	versus the mean arterial pressure. The red open and solid data points indicate hypertensive
567	patients without (HT-) and with intake of antihypertensive medication (HT+), respectively,
568	and the blue open and solid data points indicate normotensive participants without (NT-) and
569	with intake of antihypertensive medication (NT+), respectively. * indicates significant
570	associations. Note that the regression line aims to improve visualization, as it is not corrected
571	for age and sex.
572	
73	Figure 2. Blood-brain barrier (BBB) leakage in the cortex for the three hypertensive patient
574	subgroups. NT+ indicates normotensive participants with intake of antihypertensive
575	medication, HT- and HT+ hypertensive patients without and with intake of antihypertensive
576	medication, respectively. A trend can be observed between the NT+ and the HT+ group. Note
577	that the combined HT- and HT+ group shows a significant difference with NT+ group.
578	
579	
580	
581	
582	
583	
584	
585	
586	
587	
588	

- Table 1: Characteristics of hypertensive patients and normotensive control participants. 589
- Significant differences are depicted in bold. 590
- 591

Participant characteristics	Hypertensive	Normotensive	p-value
	(<i>n</i> = 22)	(n =19)	
Age (years), mean (SD)	66.0 (7.5)	61.8 (8.9)	0.107
Male, <i>n</i> (%)	8 (36)	11 (58)	0.217
Systolic blood pressure (mmHg), mean (SD)	129.1 (17.2)	120.4 (8.2)	0.042
Diastolic blood pressure (mmHg), mean (SD)	73.6 (8.2)	72.0 (7.6)	0.523
Mean arterial pressure (mmHg), mean (SD)	95.7 (12.9)	90.7 (7.7)	0.137
Blood pressure medication groups			
- ACE inhibitors & ARBs, n (%)	13 (59)	0	N/A
⁻ Beta-blockers, n (%)	5 (23)	0	N/A
- Calcium Antagonists, n (%)	3 (14)	0	N/A
- Diuretics, n (%)	4 (18)	0	N/A
Cardiovascular risk factors			
Hypercholesterolemia, n (%)	3 (14)	2 (11)	1.000
Triglyceriden, (mean (SD))	1.4 (0.7)	1.0 (0.3)	0.062
Hematocrit, (mean (SD))	0.43 (0.04)	0.45 (0.03)	0.339
Smoking, n (%)	0 (0)	0 (0)	N/A
History of smoking, n (%)	11 (50)	6 (32)	0.342
Body mass index in kg/m ² (mean (SD))	26.7 (3.0)	25.0 (3.6)	0.126
Alcohol (units per week (SD))	6.2 (7.9)	5.2 (6.3)	0.640

Imaging markers			
Fazekas score, 0/1/2/3, n (%)	14 (64)/5 (23)/	12 (63)/7 (37)/	0.464
	2 (9)/1 (5)	0 (0)/0 (0)	
PVS scores			
BG, 0/1/2/3, n (%)	4 (18)/14 (64)/	7 (37)/10 (53)/	
	3 (14)/ 1 (5)	2 (11)/0 (0)	0.715
CSO, 0/1/2/3, n (%)	0 (0)/5 (23)/	3 (16)/2 (11)/	
	9 (41)/ 8 (36)	8 (42)/5 (26)	0.235
Lacunar infarcts, n (%)	2 (9)	0 (0)	0.490
Cerebral microbleeds, n (%)	0 (0)	0 (0)	N/A
Total cSVD score, 0/1/2/3/4, n (%)	4 (18)/14 (64)/	6 (32)/ 12(63)/	
	4 (18)/0 (0)/0 (0)	0 (0)/ 0(0)/0 (0)	0.147

592 *ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blockers; PVS,

perivascular spaces; BG, basal ganglia; CSO, centrum semiovale; cSVD, cerebral small vessel 593 594 disease.

595

- 596 Table 2: Comparison of K_i and v_p between hypertensive patients and normative control participants, obtained by regression analysis adjusted for
- 597 age and sex. Significant differences are depicted in bold.
- *BBB indicates blood-brain barrier; MAP, mean arterial pressure; K_i , blood-brain barrier leakage; v_p , blood plasma volume fraction; WM, white
- 599 matter; GM, grey matter.

K_i	(*10 ⁻⁴)
-------	----------------------

Vp (*10⁻²)

Brain region I	TT ()		Standardized				Standardized	1
	Hypertensive	Normotensive	β	p-value	p-value Hypertensive	Normotensive	β	p-value
Total WM	4.23 ± 1.98	4.61 ± 1.64	0.026	0.847	3.12 ± 0.93	2.98 ± 0.80	0.216	0.095
Total GM	6.59 ± 1.85	7.08 ± 1.75	-0.016	0.900	4.27 ± 0.93	4.04 ± 0.87	0.257	0.049
Cortical GM	6.58 ± 1.83	7.05 ± 1.69	-0.010	0.940	4.23 ± 0.93	4.01 ± 0.84	0.263	0.042
Deep GM	3.61 ± 2.42	3.95 ± 2.00	0.043	0.683	3.30 ± 1.05	2.95 ± 1.03	0.276	0.031

- 600 Table 3: Multivariable linear regression analyses were performed to obtain the association
- between BBB leakage rate and blood plasma volume fraction, and blood pressure measures,
- adjusted for age and sex. Significant differences are depicted in bold.

	Systolic blood	tolic blood Diastolic blood			Mean arterial		
	pressure		pressure		pressure		
Brain region	Standardized β	p-value	Standardized β	p-value	Standardized β	p-value	
<u>K_i</u>							
Total WM	0.049	0.705	0.168	0.199	0.102	0.426	
Total GM	0.227	0.052	0.253	0.035	0.271	0.019	
Cortical GM	0.246	0.043	0.271	0.031	0.291	0.015	
Deep GM	0.098	0.326	0.144	0.159	0.130	0.188	
<u>v</u> _p							
Total WM	0.076	0.546	-0.094	0.468	-0.001	0.995	
Total GM	-0.061	0.632	-0.245	0.058	-0.143	0.260	
Cortical GM	-0.061	0.632	-0.250	0.051	-0.148	0.239	
Deep GM	-0.033	0.796	-0.152	0.238	-0.085	0.498	

603

604 *MAP indicates mean arterial pressure; K_i , blood-brain barrier leakage; v_p , blood plasma

605 volume fraction; WM, white matter; GM, grey matter




Figure 1: Scatterplots of the blood-brain barrier leakage rate in the four regions of interest versus the mean arterial pressure. The red open and solid data points indicate hypertensive patients without (HT-) and with intake of antihypertensive medication (HT+), respectively, and the blue open and solid data points indicate normotensive participants without (NT-) and with intake of antihypertensive medication (NT+), respectively. * indicates significant associations. Note that the regression line aims to improve visualization, as it is not corrected for age and sex.




Figure 2. Blood-brain barrier (BBB) leakage in the cortex for the three hypertensive patient subgroups. NT+ indicates normotensive participants with intake of antihypertensive medication, HT- and HT+ hypertensive patients without and with intake of antihypertensive medication, respectively. A trend can be observed between the NT+ and the HT+ group. Note that the combined HT- and HT+ group shows a significant difference with NT+ group.